Review



monarch external trigeminal nerve stimulation (etns) system  (NeuroSigma)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    NeuroSigma monarch external trigeminal nerve stimulation (etns) system
    Monarch External Trigeminal Nerve Stimulation (Etns) System, supplied by NeuroSigma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trigeminal+nerve+stimulation/trigeminal+nerve+stimulation/pm40086372-88-7-14
    Average 90 stars, based on 1 article reviews
    monarch external trigeminal nerve stimulation (etns) system - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: The potential use of trigeminal nerve stimulation in the treatment of epilepsy.
    Article Snippet: Financial & competing interests disclosure IA Cook, CP Kealey and CM DeGiorgio are named as inventors on patents and/or patent applications concerning trigeminal nerve stimulation that they assigned to the Regents of the Uni- versity of California (UC) and/or NeuroSigma, Inc. All three phy- sicians also have leadership roles at NeuroSigma, Inc,. the ex- clusive worldwide licensee of UC’s intellectual property on TNS, including employment and stock options.

    Article Title: Issue Overview
    Article Snippet: Learning Objectives Upon completion of the Continuum: Lifelong Learning in Neurology Epilepsy issue, participants will be able to: ► Discuss the controversy regarding the terminology for seizures and epilepsy and describe the newly proposed classification ► Apply strategies for the diagnosis and evaluation of patients with seizure disorders using EEG and neuroimaging techniques ► Treat patients with seizures and epilepsy using antiepileptic drug therapy ► Recognize important therapeutic issues in pediatric epilepsy ► Identify patients nonepileptic behavioral disorders and best treatment approaches for them, including cognitive behavioral therapy ► Manage patients with acute repetitive seizures and status epilepticus ► Identify individuals with surgically remediable epileptic syndromes who may be candidates for epilepsy surgery and realize when referral for surgery should be considered

    Article Title: Trigeminal Nerve Stimulation for Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder.
    Article Snippet: Objectives: External stimulation of the trigeminal nerve (eTNS) is an emerging neuromodulation therapy for epilepsy and depression.. Preliminary studies suggest it has an excellent safety profile and is associated with significant improvements in seizures and mood.. Neuroanatomical projections of the trigeminal system suggest eTNS may alter activity in structures regulating mood, anxiety, and sleep.

    Article Title: Implantable electroacupuncture device and method for treating depression, bipolar disorder and anxiety
    Article Snippet: The therapy platforms used by NeuroSigma at the present comprise Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).

    Article Title: Contributors
    Article Snippet: Professor of Neurology, University of South Florida, Tampa, Florida; Director, Comprehensive Epilepsy Program, Tampa General Hospital, Tampa, Florida *Dr Benbadis is a member of the speakers bureau and serves as a consultant for Cyberonics, Inc, GlaxoSmithKline, Lundbeck, Supernus Pharmaceuticals, Inc, and UCB; serves as an editor for Medscape-WebMD, LLC; and receives research support from Lundbeck, Sunovion Pharmaceuticals, Inc, Supernus Pharmaceuticals, Inc, and UCB.. †Dr Benbadis reports no disclosure.. LIFELONG LEARNING IN NEUROLOGY®

    Article Title: Epilepsy & behavior: 15th anniversary research on omega-3 fatty acids for epilepsy.
    Article Snippet: The authors congratulate Dr. Steven Schachter and the editorial board on the 15th anniversary of Epilepsy & Behavior.. Epilepsy & Behavior has taken the lead in publishing early research on alternative treatments for epilepsy and has provided a podium in which basic and translational research could be rapidly reported.. Over time, the quality of papers and the impact of the journal have increased, and Epilepsy & Behavior has become a go-to journal for cutting-edge research on epilepsy.

    Article Title: The SUDEP Risk Inventory: Association with postictal generalized EEG suppression.
    Article Snippet: To help identify patients at greatest risk for sudden unexpected death in epilepsy (SUDEP), screening inventories like the SUDEP-7 Inventory can be useful.. In this study, we examined the strength of association between this inventory’s risk factors and postictal generalized EEG suppression (PGES), a biomarker of SUDEP risk.. We reanalyzed data from an epilepsy monitoring unit study of 37 children.

    Article Title: An eight-week, open-trial, pilot feasibility study of trigeminal nerve stimulation in youth with attention-deficit/hyperactivity disorder.
    Article Snippet: Background: This study examined the potential feasibility and utility of trigeminal nerve stimulation (TNS) for attention-deficit/hyperactivity disorder (ADHD) in youth.. Methods: Twenty-four participants ages 7e14 with ADHD enrolled in an 8-week open trial of TNS administered nightly during sleep, and were assessed weekly with parentand physician-completed measures of ADHD symptoms and executive functioning as well as measures of treatment compliance, adverse events, and side effects.. Computerized tests of cognitive functioning were administered at baseline and weeks 4 and 8.



    Similar Products

    90
    NeuroSigma monarch external trigeminal nerve stimulation (etns) system
    Monarch External Trigeminal Nerve Stimulation (Etns) System, supplied by NeuroSigma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trigeminal+nerve+stimulation/trigeminal+nerve+stimulation/pm40086372-88-7-14
    Average 90 stars, based on 1 article reviews
    monarch external trigeminal nerve stimulation (etns) system - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    NeuroSigma non-invasive stimulation of the trigeminal nerve
    Non Invasive Stimulation Of The Trigeminal Nerve, supplied by NeuroSigma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trigeminal+nerve+stimulation/trigeminal+nerve+stimulation/us12005251-108-0-25
    Average 90 stars, based on 1 article reviews
    non-invasive stimulation of the trigeminal nerve - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    NeuroSigma external trigeminal nerve stimulation
    A brief history of <t>Trigeminal</t> Nerve <t>Stimulation.</t> TNS was first used in 1974 to assess the neural control of cerebral blood flow. Since then, it has been applied clinically in migraine, epilepsy, depression, PTSD, fibromyalgia, SAD, cognitive/balance dysfunction, pediatric ADHD, PVS, SAH, and secondary issues due to mTBI. In 2014, Cefaly was approved by the FDA for treatment of migraine, Neurosigma was approved in 2019 for pediatric ADHD, and PoNS was approved in 2023 for cognitive/balance dysfunction. Preclinically, the efficacy of TNS has additionally been assessed in TBI, HS, TBI + HS, and ischemic stroke. In the past decade, the effects and mechanisms of TNS within the brain and throughout the body have been expanded upon. (This figure was generated using BioRender.com) (AcH: acetylcholine: ACN: anticorrelated networks; ADHD: attention deficit and hyperactivity disorder; ANS: autonomic nervous system; BBB: blood–brain barrier; BOLD: Blood Oxygenation Level Dependent; CB: cingulum bundle; CBF: cerebral blood flow; CGRP: Calcitonin gene-related peptide; CVR: cerebrovascular resistance; HR: heart rate; HS: hemorrhagic shock; mTBI: mild traumatic brain injury; PFC: prefrontal cortex; PTSD: post-traumatic stress disorder; PVS: persistent vegetative state; SAD: social anxiety disorder; SAH: subarachnoid hemorrhage; TBI: traumatic brain injury; TNS: trigeminal nerve stimulation;)
    External Trigeminal Nerve Stimulation, supplied by NeuroSigma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trigeminal+nerve+stimulation/trigeminal+nerve+stimulation/pmc10717521-29-5-9
    Average 90 stars, based on 1 article reviews
    external trigeminal nerve stimulation - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Bioland Scientific trigeminal nerve stimulation
    A brief history of <t>Trigeminal</t> Nerve <t>Stimulation.</t> TNS was first used in 1974 to assess the neural control of cerebral blood flow. Since then, it has been applied clinically in migraine, epilepsy, depression, PTSD, fibromyalgia, SAD, cognitive/balance dysfunction, pediatric ADHD, PVS, SAH, and secondary issues due to mTBI. In 2014, Cefaly was approved by the FDA for treatment of migraine, Neurosigma was approved in 2019 for pediatric ADHD, and PoNS was approved in 2023 for cognitive/balance dysfunction. Preclinically, the efficacy of TNS has additionally been assessed in TBI, HS, TBI + HS, and ischemic stroke. In the past decade, the effects and mechanisms of TNS within the brain and throughout the body have been expanded upon. (This figure was generated using BioRender.com) (AcH: acetylcholine: ACN: anticorrelated networks; ADHD: attention deficit and hyperactivity disorder; ANS: autonomic nervous system; BBB: blood–brain barrier; BOLD: Blood Oxygenation Level Dependent; CB: cingulum bundle; CBF: cerebral blood flow; CGRP: Calcitonin gene-related peptide; CVR: cerebrovascular resistance; HR: heart rate; HS: hemorrhagic shock; mTBI: mild traumatic brain injury; PFC: prefrontal cortex; PTSD: post-traumatic stress disorder; PVS: persistent vegetative state; SAD: social anxiety disorder; SAH: subarachnoid hemorrhage; TBI: traumatic brain injury; TNS: trigeminal nerve stimulation;)
    Trigeminal Nerve Stimulation, supplied by Bioland Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trigeminal+nerve+stimulation/trigeminal+nerve+stimulation/pm37270025-12-96-66
    Average 90 stars, based on 1 article reviews
    trigeminal nerve stimulation - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Koehler Instrument trigeminal nerve stimulation
    A brief history of <t>Trigeminal</t> Nerve <t>Stimulation.</t> TNS was first used in 1974 to assess the neural control of cerebral blood flow. Since then, it has been applied clinically in migraine, epilepsy, depression, PTSD, fibromyalgia, SAD, cognitive/balance dysfunction, pediatric ADHD, PVS, SAH, and secondary issues due to mTBI. In 2014, Cefaly was approved by the FDA for treatment of migraine, Neurosigma was approved in 2019 for pediatric ADHD, and PoNS was approved in 2023 for cognitive/balance dysfunction. Preclinically, the efficacy of TNS has additionally been assessed in TBI, HS, TBI + HS, and ischemic stroke. In the past decade, the effects and mechanisms of TNS within the brain and throughout the body have been expanded upon. (This figure was generated using BioRender.com) (AcH: acetylcholine: ACN: anticorrelated networks; ADHD: attention deficit and hyperactivity disorder; ANS: autonomic nervous system; BBB: blood–brain barrier; BOLD: Blood Oxygenation Level Dependent; CB: cingulum bundle; CBF: cerebral blood flow; CGRP: Calcitonin gene-related peptide; CVR: cerebrovascular resistance; HR: heart rate; HS: hemorrhagic shock; mTBI: mild traumatic brain injury; PFC: prefrontal cortex; PTSD: post-traumatic stress disorder; PVS: persistent vegetative state; SAD: social anxiety disorder; SAH: subarachnoid hemorrhage; TBI: traumatic brain injury; TNS: trigeminal nerve stimulation;)
    Trigeminal Nerve Stimulation, supplied by Koehler Instrument, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trigeminal+nerve+stimulation/trigeminal+nerve+stimulation/pm35051524-203-3-41
    Average 90 stars, based on 1 article reviews
    trigeminal nerve stimulation - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Northwell Health Laboratories trigeminal nerve stimulation
    A brief history of <t>Trigeminal</t> Nerve <t>Stimulation.</t> TNS was first used in 1974 to assess the neural control of cerebral blood flow. Since then, it has been applied clinically in migraine, epilepsy, depression, PTSD, fibromyalgia, SAD, cognitive/balance dysfunction, pediatric ADHD, PVS, SAH, and secondary issues due to mTBI. In 2014, Cefaly was approved by the FDA for treatment of migraine, Neurosigma was approved in 2019 for pediatric ADHD, and PoNS was approved in 2023 for cognitive/balance dysfunction. Preclinically, the efficacy of TNS has additionally been assessed in TBI, HS, TBI + HS, and ischemic stroke. In the past decade, the effects and mechanisms of TNS within the brain and throughout the body have been expanded upon. (This figure was generated using BioRender.com) (AcH: acetylcholine: ACN: anticorrelated networks; ADHD: attention deficit and hyperactivity disorder; ANS: autonomic nervous system; BBB: blood–brain barrier; BOLD: Blood Oxygenation Level Dependent; CB: cingulum bundle; CBF: cerebral blood flow; CGRP: Calcitonin gene-related peptide; CVR: cerebrovascular resistance; HR: heart rate; HS: hemorrhagic shock; mTBI: mild traumatic brain injury; PFC: prefrontal cortex; PTSD: post-traumatic stress disorder; PVS: persistent vegetative state; SAD: social anxiety disorder; SAH: subarachnoid hemorrhage; TBI: traumatic brain injury; TNS: trigeminal nerve stimulation;)
    Trigeminal Nerve Stimulation, supplied by Northwell Health Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trigeminal+nerve+stimulation/bioelectronic+medicine/10__1089_slash_neu__2021__29111__abstracts-2192-1-44
    Average 90 stars, based on 1 article reviews
    trigeminal nerve stimulation - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Neuros Medical Inc trigeminal nerve stimulation
    A brief history of <t>Trigeminal</t> Nerve <t>Stimulation.</t> TNS was first used in 1974 to assess the neural control of cerebral blood flow. Since then, it has been applied clinically in migraine, epilepsy, depression, PTSD, fibromyalgia, SAD, cognitive/balance dysfunction, pediatric ADHD, PVS, SAH, and secondary issues due to mTBI. In 2014, Cefaly was approved by the FDA for treatment of migraine, Neurosigma was approved in 2019 for pediatric ADHD, and PoNS was approved in 2023 for cognitive/balance dysfunction. Preclinically, the efficacy of TNS has additionally been assessed in TBI, HS, TBI + HS, and ischemic stroke. In the past decade, the effects and mechanisms of TNS within the brain and throughout the body have been expanded upon. (This figure was generated using BioRender.com) (AcH: acetylcholine: ACN: anticorrelated networks; ADHD: attention deficit and hyperactivity disorder; ANS: autonomic nervous system; BBB: blood–brain barrier; BOLD: Blood Oxygenation Level Dependent; CB: cingulum bundle; CBF: cerebral blood flow; CGRP: Calcitonin gene-related peptide; CVR: cerebrovascular resistance; HR: heart rate; HS: hemorrhagic shock; mTBI: mild traumatic brain injury; PFC: prefrontal cortex; PTSD: post-traumatic stress disorder; PVS: persistent vegetative state; SAD: social anxiety disorder; SAH: subarachnoid hemorrhage; TBI: traumatic brain injury; TNS: trigeminal nerve stimulation;)
    Trigeminal Nerve Stimulation, supplied by Neuros Medical Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trigeminal+nerve+stimulation/trigeminal+nerve+stimulation/pm30272245-20-26-15
    Average 90 stars, based on 1 article reviews
    trigeminal nerve stimulation - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    NeuroSigma external trigeminal nerve stimulation system
    A brief history of <t>Trigeminal</t> Nerve <t>Stimulation.</t> TNS was first used in 1974 to assess the neural control of cerebral blood flow. Since then, it has been applied clinically in migraine, epilepsy, depression, PTSD, fibromyalgia, SAD, cognitive/balance dysfunction, pediatric ADHD, PVS, SAH, and secondary issues due to mTBI. In 2014, Cefaly was approved by the FDA for treatment of migraine, Neurosigma was approved in 2019 for pediatric ADHD, and PoNS was approved in 2023 for cognitive/balance dysfunction. Preclinically, the efficacy of TNS has additionally been assessed in TBI, HS, TBI + HS, and ischemic stroke. In the past decade, the effects and mechanisms of TNS within the brain and throughout the body have been expanded upon. (This figure was generated using BioRender.com) (AcH: acetylcholine: ACN: anticorrelated networks; ADHD: attention deficit and hyperactivity disorder; ANS: autonomic nervous system; BBB: blood–brain barrier; BOLD: Blood Oxygenation Level Dependent; CB: cingulum bundle; CBF: cerebral blood flow; CGRP: Calcitonin gene-related peptide; CVR: cerebrovascular resistance; HR: heart rate; HS: hemorrhagic shock; mTBI: mild traumatic brain injury; PFC: prefrontal cortex; PTSD: post-traumatic stress disorder; PVS: persistent vegetative state; SAD: social anxiety disorder; SAH: subarachnoid hemorrhage; TBI: traumatic brain injury; TNS: trigeminal nerve stimulation;)
    External Trigeminal Nerve Stimulation System, supplied by NeuroSigma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trigeminal+nerve+stimulation/trigeminal+nerve+stimulation/pm31108410-29-2-14
    Average 90 stars, based on 1 article reviews
    external trigeminal nerve stimulation system - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    NeuroSigma non-invasive trigeminal nerve stimulator
    A brief history of <t>Trigeminal</t> Nerve <t>Stimulation.</t> TNS was first used in 1974 to assess the neural control of cerebral blood flow. Since then, it has been applied clinically in migraine, epilepsy, depression, PTSD, fibromyalgia, SAD, cognitive/balance dysfunction, pediatric ADHD, PVS, SAH, and secondary issues due to mTBI. In 2014, Cefaly was approved by the FDA for treatment of migraine, Neurosigma was approved in 2019 for pediatric ADHD, and PoNS was approved in 2023 for cognitive/balance dysfunction. Preclinically, the efficacy of TNS has additionally been assessed in TBI, HS, TBI + HS, and ischemic stroke. In the past decade, the effects and mechanisms of TNS within the brain and throughout the body have been expanded upon. (This figure was generated using BioRender.com) (AcH: acetylcholine: ACN: anticorrelated networks; ADHD: attention deficit and hyperactivity disorder; ANS: autonomic nervous system; BBB: blood–brain barrier; BOLD: Blood Oxygenation Level Dependent; CB: cingulum bundle; CBF: cerebral blood flow; CGRP: Calcitonin gene-related peptide; CVR: cerebrovascular resistance; HR: heart rate; HS: hemorrhagic shock; mTBI: mild traumatic brain injury; PFC: prefrontal cortex; PTSD: post-traumatic stress disorder; PVS: persistent vegetative state; SAD: social anxiety disorder; SAH: subarachnoid hemorrhage; TBI: traumatic brain injury; TNS: trigeminal nerve stimulation;)
    Non Invasive Trigeminal Nerve Stimulator, supplied by NeuroSigma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trigeminal+nerve+stimulation/trigeminal+nerve+stimulation/pm31406329-127-8-14
    Average 90 stars, based on 1 article reviews
    non-invasive trigeminal nerve stimulator - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    A brief history of Trigeminal Nerve Stimulation. TNS was first used in 1974 to assess the neural control of cerebral blood flow. Since then, it has been applied clinically in migraine, epilepsy, depression, PTSD, fibromyalgia, SAD, cognitive/balance dysfunction, pediatric ADHD, PVS, SAH, and secondary issues due to mTBI. In 2014, Cefaly was approved by the FDA for treatment of migraine, Neurosigma was approved in 2019 for pediatric ADHD, and PoNS was approved in 2023 for cognitive/balance dysfunction. Preclinically, the efficacy of TNS has additionally been assessed in TBI, HS, TBI + HS, and ischemic stroke. In the past decade, the effects and mechanisms of TNS within the brain and throughout the body have been expanded upon. (This figure was generated using BioRender.com) (AcH: acetylcholine: ACN: anticorrelated networks; ADHD: attention deficit and hyperactivity disorder; ANS: autonomic nervous system; BBB: blood–brain barrier; BOLD: Blood Oxygenation Level Dependent; CB: cingulum bundle; CBF: cerebral blood flow; CGRP: Calcitonin gene-related peptide; CVR: cerebrovascular resistance; HR: heart rate; HS: hemorrhagic shock; mTBI: mild traumatic brain injury; PFC: prefrontal cortex; PTSD: post-traumatic stress disorder; PVS: persistent vegetative state; SAD: social anxiety disorder; SAH: subarachnoid hemorrhage; TBI: traumatic brain injury; TNS: trigeminal nerve stimulation;)

    Journal: Bioelectronic Medicine

    Article Title: Trigeminal nerve stimulation: a current state-of-the-art review

    doi: 10.1186/s42234-023-00128-z

    Figure Lengend Snippet: A brief history of Trigeminal Nerve Stimulation. TNS was first used in 1974 to assess the neural control of cerebral blood flow. Since then, it has been applied clinically in migraine, epilepsy, depression, PTSD, fibromyalgia, SAD, cognitive/balance dysfunction, pediatric ADHD, PVS, SAH, and secondary issues due to mTBI. In 2014, Cefaly was approved by the FDA for treatment of migraine, Neurosigma was approved in 2019 for pediatric ADHD, and PoNS was approved in 2023 for cognitive/balance dysfunction. Preclinically, the efficacy of TNS has additionally been assessed in TBI, HS, TBI + HS, and ischemic stroke. In the past decade, the effects and mechanisms of TNS within the brain and throughout the body have been expanded upon. (This figure was generated using BioRender.com) (AcH: acetylcholine: ACN: anticorrelated networks; ADHD: attention deficit and hyperactivity disorder; ANS: autonomic nervous system; BBB: blood–brain barrier; BOLD: Blood Oxygenation Level Dependent; CB: cingulum bundle; CBF: cerebral blood flow; CGRP: Calcitonin gene-related peptide; CVR: cerebrovascular resistance; HR: heart rate; HS: hemorrhagic shock; mTBI: mild traumatic brain injury; PFC: prefrontal cortex; PTSD: post-traumatic stress disorder; PVS: persistent vegetative state; SAD: social anxiety disorder; SAH: subarachnoid hemorrhage; TBI: traumatic brain injury; TNS: trigeminal nerve stimulation;)

    Article Snippet: , Depression , 8 weeks external trigeminal nerve stimulation (NeuroSigma predecessor) , Pharmacological resistant major depression , Not stated , ↓ HDRS and BDI scores , None stated , Schrader et al .

    Techniques: Control, Generated

    Clinical usage of TNS

    Journal: Bioelectronic Medicine

    Article Title: Trigeminal nerve stimulation: a current state-of-the-art review

    doi: 10.1186/s42234-023-00128-z

    Figure Lengend Snippet: Clinical usage of TNS

    Article Snippet: , Depression , 8 weeks external trigeminal nerve stimulation (NeuroSigma predecessor) , Pharmacological resistant major depression , Not stated , ↓ HDRS and BDI scores , None stated , Schrader et al .

    Techniques: Biomarker Discovery, Functional Assay, Activation Assay

    The underlying mechanisms of trigeminal nerve stimulation’s effects. The main mechanisms of TNS can be split into three main categories, 1)the release of vasoactive neuropeptides, 2)the modulation of neurotransmission, and 3)modulation of the ANS. The direct release of vasoactive neuropeptides such as CGRP, PACAP, VIP, SP, and NO from trigeminal and parasympathetic nerve fibers underlies the observed anti-inflammatory and cerebral vasodilatory effects of TNS. Via the increase of hypocretin and dopamine, there is an increase wakefulness and psychological dysfunction. The upregulation of eNOS and upregulation of NMDA receptors and glutamate result in bimodal modulation of BBB permeability, while the downregulation of NMDA receptors decreases glutamatergic transmission and increases GABA, thus modulating CSDs. Systemically, the cholinergic and catecholaminergic pathways of the ANS are harnessed by TNS. Through the cholinergic pathway of the PNS and upregulation of acetylcholine, cardiac performance is modulated when the acetylcholine binds to the muscarinic receptors on the heart. This cholinergic pathway is hypothesized to be the mechanism which gives rise to TNS’ systemic anti-inflammation as well. The released acetylcholine would stimulate α7-nicotinic receptors on splenic macrophages and decrease proinflammatory cytokine production. Concurrent upregulation of the SNS and the catecholaminergic pathway induces the release of norepinephrine peripheral vasoconstriction, leading to increased blood pressure and CBF. (This figure was generated using BioRender.com) (Ach: acetylcholine; ANS: autonomic nervous system; BBB: blood–brain barrier; CGRP: Calcitonin gene-related peptide; CO: cardiac output; CRH: corticotropin releasing hormone; DMN: dorsal motor nucleus; eNOS: endothelial nitric oxide synthase; GABA: gamma-aminobutyric acid; KF: Kölliker-FuseNO: nitric oxide; L: leukocyte; MAP: mean arterial pressure; MDH: medullary dorsal horn; MG: microglia; NA: nucleus accumbens; NE/E: norepinephrine/epinephrine; NMDA: N-methyl-d-aspartate; NTS: nucleus tractus solitarius; PACAP: pituitary adenylate cyclase-activating peptide; PNS: parasympathetic nervous system; RVLM: rostral ventrolateral medulla; SNS: sympathetic nervous system; SP: Substance P; SV: stroke volume; TG: trigeminal ganglion; TNS: trigeminal nerve stimulation; VIP: vasoactive intestinal peptide; VN: vagus nerve; VTA: ventral tegmental area)

    Journal: Bioelectronic Medicine

    Article Title: Trigeminal nerve stimulation: a current state-of-the-art review

    doi: 10.1186/s42234-023-00128-z

    Figure Lengend Snippet: The underlying mechanisms of trigeminal nerve stimulation’s effects. The main mechanisms of TNS can be split into three main categories, 1)the release of vasoactive neuropeptides, 2)the modulation of neurotransmission, and 3)modulation of the ANS. The direct release of vasoactive neuropeptides such as CGRP, PACAP, VIP, SP, and NO from trigeminal and parasympathetic nerve fibers underlies the observed anti-inflammatory and cerebral vasodilatory effects of TNS. Via the increase of hypocretin and dopamine, there is an increase wakefulness and psychological dysfunction. The upregulation of eNOS and upregulation of NMDA receptors and glutamate result in bimodal modulation of BBB permeability, while the downregulation of NMDA receptors decreases glutamatergic transmission and increases GABA, thus modulating CSDs. Systemically, the cholinergic and catecholaminergic pathways of the ANS are harnessed by TNS. Through the cholinergic pathway of the PNS and upregulation of acetylcholine, cardiac performance is modulated when the acetylcholine binds to the muscarinic receptors on the heart. This cholinergic pathway is hypothesized to be the mechanism which gives rise to TNS’ systemic anti-inflammation as well. The released acetylcholine would stimulate α7-nicotinic receptors on splenic macrophages and decrease proinflammatory cytokine production. Concurrent upregulation of the SNS and the catecholaminergic pathway induces the release of norepinephrine peripheral vasoconstriction, leading to increased blood pressure and CBF. (This figure was generated using BioRender.com) (Ach: acetylcholine; ANS: autonomic nervous system; BBB: blood–brain barrier; CGRP: Calcitonin gene-related peptide; CO: cardiac output; CRH: corticotropin releasing hormone; DMN: dorsal motor nucleus; eNOS: endothelial nitric oxide synthase; GABA: gamma-aminobutyric acid; KF: Kölliker-FuseNO: nitric oxide; L: leukocyte; MAP: mean arterial pressure; MDH: medullary dorsal horn; MG: microglia; NA: nucleus accumbens; NE/E: norepinephrine/epinephrine; NMDA: N-methyl-d-aspartate; NTS: nucleus tractus solitarius; PACAP: pituitary adenylate cyclase-activating peptide; PNS: parasympathetic nervous system; RVLM: rostral ventrolateral medulla; SNS: sympathetic nervous system; SP: Substance P; SV: stroke volume; TG: trigeminal ganglion; TNS: trigeminal nerve stimulation; VIP: vasoactive intestinal peptide; VN: vagus nerve; VTA: ventral tegmental area)

    Article Snippet: , Depression , 8 weeks external trigeminal nerve stimulation (NeuroSigma predecessor) , Pharmacological resistant major depression , Not stated , ↓ HDRS and BDI scores , None stated , Schrader et al .

    Techniques: Permeability, Transmission Assay, Generated

    The effects, therapeutic targets, and unique properties of TNS. The effects of TNS can be separated into 3 main categories: effects on the CNS, the ANS, and the peripheral vasculature. Based on these effects, and particularly the effects on the CNS, many current therapeutic targets are focused on neurological, psychological, neuromuscular, and cerebrovascular pathologies. Already, some are approved for clinical usage, and others are in clinical testing. TNS is also currently under preclinical trials for acute/traumatic conditions, such as TBI, stroke, and hemorrhagic shock. Its multitudinous effects may allow it to be used therapeutically for the treatment of retinopathy, spinal cord injury, inflammatory dysfunctions, chronic cerebral hypoperfusion, and drug addiction. Setting it apart from other forms of bioelectronic medicine, TNS is able to cause direct cerebrovasodilation, increase hypocretin expression, and induce peripheral vasoconstriction. It is also the only one so far tried for balance difficulties due to mTBI. Uniquely, TNS also has diagnostic potentials in regard to Parkinson’s disease and hemorrhagic shock severity, which broadens its potential applications. (This figure was generated using BioRender.com) (ADHD: attention deficit and hyperactivity disorder; BBB: blood–brain barrier; CNS: central nervous system; CSD: cortical spreading depolarization; HS: hemorrhagic shock; IBD: irritable bowel disease; mTBI: mild traumatic brain injury; PNS: parasympathetic nervous system; PTSD: post-traumatic stress disorder; PVS: persistent vegetative state; SAD: social anxiety disorder; SAH: subarachnoid hemorrhage; SNS: sympathetic nervous system TBI: traumatic brain injury; TNS: trigeminal nerve stimulation)

    Journal: Bioelectronic Medicine

    Article Title: Trigeminal nerve stimulation: a current state-of-the-art review

    doi: 10.1186/s42234-023-00128-z

    Figure Lengend Snippet: The effects, therapeutic targets, and unique properties of TNS. The effects of TNS can be separated into 3 main categories: effects on the CNS, the ANS, and the peripheral vasculature. Based on these effects, and particularly the effects on the CNS, many current therapeutic targets are focused on neurological, psychological, neuromuscular, and cerebrovascular pathologies. Already, some are approved for clinical usage, and others are in clinical testing. TNS is also currently under preclinical trials for acute/traumatic conditions, such as TBI, stroke, and hemorrhagic shock. Its multitudinous effects may allow it to be used therapeutically for the treatment of retinopathy, spinal cord injury, inflammatory dysfunctions, chronic cerebral hypoperfusion, and drug addiction. Setting it apart from other forms of bioelectronic medicine, TNS is able to cause direct cerebrovasodilation, increase hypocretin expression, and induce peripheral vasoconstriction. It is also the only one so far tried for balance difficulties due to mTBI. Uniquely, TNS also has diagnostic potentials in regard to Parkinson’s disease and hemorrhagic shock severity, which broadens its potential applications. (This figure was generated using BioRender.com) (ADHD: attention deficit and hyperactivity disorder; BBB: blood–brain barrier; CNS: central nervous system; CSD: cortical spreading depolarization; HS: hemorrhagic shock; IBD: irritable bowel disease; mTBI: mild traumatic brain injury; PNS: parasympathetic nervous system; PTSD: post-traumatic stress disorder; PVS: persistent vegetative state; SAD: social anxiety disorder; SAH: subarachnoid hemorrhage; SNS: sympathetic nervous system TBI: traumatic brain injury; TNS: trigeminal nerve stimulation)

    Article Snippet: , Depression , 8 weeks external trigeminal nerve stimulation (NeuroSigma predecessor) , Pharmacological resistant major depression , Not stated , ↓ HDRS and BDI scores , None stated , Schrader et al .

    Techniques: Biomarker Discovery, Expressing, Diagnostic Assay, Generated